Holen Sie sich die Stockscreener-App
1.00
3.85%
-0.04
Handel nachbörslich:
1.02
0.02
+2.00%
Schlusskurs vom Vortag:
$1.04
Offen:
$1.04
24-Stunden-Volumen:
1.29M
Relative Volume:
1.44
Marktkapitalisierung:
$90.08M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-93.61M
KGV:
-0.2915
EPS:
-3.43
Netto-Cashflow:
$-71.16M
1W Leistung:
-11.50%
1M Leistung:
-6.54%
6M Leistung:
-9.91%
1J Leistung:
-20.63%
1-Tages-Spanne:
$1.00
$1.10
1-Wochen-Bereich:
$1.00
$1.1799
52-Wochen-Spanne:
$0.97
$2.11
Immunic Inc Stock (IMUX) Company Profile
Firmenname
Immunic Inc
Sektor
Branche
Telefon
(332) 255-9818
Adresse
1200 AVENUE OF THE AMERICAS, NEW YORK
Vergleichen Sie IMUX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMUX
Immunic Inc
|
1.00 | 90.08M | 0 | -93.61M | -71.16M | -2.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Immunic Inc Stock (IMUX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-09-09 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-08-27 | Eingeleitet | B. Riley Securities | Buy |
| 2022-10-21 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-09-19 | Fortgesetzt | H.C. Wainwright | Buy |
| 2021-04-15 | Eingeleitet | Aegis Capital | Buy |
| 2021-03-24 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-10-02 | Eingeleitet | SVB Leerink | Outperform |
| 2020-08-26 | Eingeleitet | Piper Sandler | Overweight |
| 2020-08-07 | Fortgesetzt | ROTH Capital | Buy |
| 2020-07-20 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-06-05 | Eingeleitet | Wedbush | Outperform |
| 2020-05-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-03-25 | Eingeleitet | ROTH Capital | Buy |
| 2019-07-11 | Eingeleitet | Chardan Capital Markets | Buy |
Alle ansehen
Immunic Inc Aktie (IMUX) Neueste Nachrichten
Brokerages Set Immunic, Inc. (NASDAQ:IMUX) PT at $11.80 - Defense World
Immunic CEO Daniel Vitt secures new employment terms - Investing.com
Immunic CEO Daniel Vitt secures new employment terms By Investing.com - Investing.com UK
Immunic, Inc. (NASDAQ:IMUX) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Immunic, Inc. (NASDAQ:IMUX) Short Interest Update - Defense World
Immunic, Inc. (NASDAQ:IMUX) Short Interest Up 10.3% in November - MarketBeat
Immunic CEO Dr Daniel Vitt on successful 2024, with more to come in the year ahead - Proactive financial news
Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update - The Eastern Progress Online
Janus Henderson Group PLC Sells 1,974,566 Shares of Immunic, Inc. (NASDAQ:IMUX) - MarketBeat
Immunic CSO discusses breaking the IBD stigma to mark Crohn's and Colitis Awareness Week - Proactive Investors UK
Broad Benefits Of Immunic MS Drug Could Transform Treatment - News & Insights
B. Riley Has Bearish Forecast for Immunic FY2024 Earnings - Defense World
B. Riley Estimates Immunic's FY2024 Earnings (NASDAQ:IMUX) - MarketBeat
FY2024 Earnings Estimate for Immunic Issued By HC Wainwright - Defense World
IMUXImmunic, Inc. Latest Stock News & Market Updates - StockTitan
HC Wainwright Begins Coverage on Immunic (NASDAQ:IMUX) - Defense World
HC Wainwright Estimates Immunic’s Q4 Earnings (NASDAQ:IMUX) - Defense World
Immunic, Inc. to Participate in Investor Conference in December - The Malaysian Reserve
Immunic to present at Piper Sandler 36th Annual Healthcare Conference - Proactive Investors USA
What is HC Wainwright's Estimate for Immunic Q4 Earnings? - MarketBeat
H.C. Wainwright bullish on Immunic stock—Phase 3 MS drug de-risks outlook - Investing.com Nigeria
H.C. Wainwright bullish on Immunic stock—Phase 3 MS drug de-risks outlook By Investing.com - Investing.com South Africa
Immunic initiated with a Buy at H.C. Wainwright - TipRanks
Immunic, Inc. (NASDAQ:IMUX) Receives $12.25 Average Price Target from Analysts - MarketBeat
Immunic, Inc. (NASDAQ:IMUX) Short Interest Up 29.7% in October - Defense World
Immunic's IMU-856 shows potential in gastrointestinal health trialsICYMI - Proactive Investors UK
Avidity Partners Management LP's Strategic Acquisition in Immuni - GuruFocus.com
Richard Rudick Spends US$100k On Immunic Stock - Simply Wall St
Insider Buys Additional US$100k In Immunic Stock - Yahoo Finance
Janus Henderson Group PLC's Strategic Reduction in Immunic Inc H - GuruFocus.com
75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space | DelveInsight - The Malaysian Reserve
RTW INVESTMENTS, LP Acquires Additional Shares in Immunic Inc - GuruFocus.com
Immunic announces publication of IMU-856 data - Yahoo Finance
Director Richard Rudick Acquires 87,300 Shares of Immunic Inc (I - GuruFocus.com
Immunic director Richard Rudick buys $100,368 in stock By Investing.com - Investing.com Australia
Immunic director Richard Rudick buys $100,368 in stock - Investing.com
Immunic announces publication of IMU-856 Phase 1 trial data in peer-reviewed journal - Proactive Investors UK
Immunic reports positive Phase 1 results for celiac disease therapy published in The Lancet - Proactive Investors USA
Immunic's IMU-856 Shows Breakthrough Results in Celiac Disease Trial, Published in Lancet | IMUX Stock News - StockTitan
Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology - The Malaysian Reserve
Immunic (NASDAQ:IMUX) Stock Rating Lowered by StockNews.com - Defense World
Immunic, Inc. (NASDAQ:IMUX) Q3 2024 Earnings Call Transcript - Insider Monkey
Immunic Inc (IMUX) Q3 2024 Earnings Call Highlights: Strategic Progress Amid Financial Challenges By GuruFocus - Investing.com Canada
Immunic Inc (IMUX) Q3 2024 Earnings Call Highlights: Strategic P - GuruFocus.com
Immunic Inc (IMUX) Q3 2024 Earnings Call Highlights: Strategic Progress Amid Financial Challenges - Yahoo Finance
Immunic Reports Q3 Earnings and Provides Corporate Update - TipRanks
Immunic CEO details progress following productive third quarter - Proactive Investors Australia
Immunic, Inc. Advances MS Trials Amid Financial Update - TipRanks
Immunic, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Immunic: Q3 Earnings Snapshot - Milford Mirror
Immunic Inc (IMUX) Quarterly 10-Q Report - Quartzy
Finanzdaten der Immunic Inc-Aktie (IMUX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):